Nephros (NASDAQ:NEPH) Upgraded by Zacks Research to Hold Rating

Nephros (NASDAQ:NEPH) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Several other research firms also recently commented on NEPH. Northland Securities began coverage on Nephros in a research note on Friday, July 17th. They issued a “market perform” rating and a $4.00 price objective on the stock. Weiss Ratings cut shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. One investment analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.00.

Nephros Stock Down 2.4%

NASDAQ NEPH opened at $3.59 on Monday. Nephros has a 52 week low of $2.66 and a 52 week high of $6.42. The firm has a market capitalization of $38.98 million, a P/E ratio of 51.29 and a beta of 1.49. The company has a 50-day moving average price of $3.47 and a 200-day moving average price of $3.63.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, hitting the consensus estimate of $0.01. The firm had revenue of $5.21 million for the quarter, compared to analysts’ expectations of $5.02 million. Nephros had a net margin of 4.06% and a return on equity of 7.66%. As a group, equities research analysts anticipate that Nephros will post 0.03 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new stake in shares of Nephros in the third quarter worth about $64,000. Citadel Advisors LLC boosted its stake in Nephros by 39.2% during the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock valued at $78,000 after buying an additional 4,655 shares during the last quarter. XTX Topco Ltd grew its holdings in Nephros by 48.5% during the 4th quarter. XTX Topco Ltd now owns 21,617 shares of the company’s stock valued at $105,000 after buying an additional 7,062 shares in the last quarter. Quadrature Capital Ltd bought a new stake in Nephros in the 4th quarter worth approximately $112,000. Finally, Essex Investment Management Co. LLC raised its holdings in shares of Nephros by 57.1% during the 4th quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after acquiring an additional 14,162 shares in the last quarter. Institutional investors own 41.10% of the company’s stock.

Key Nephros News

Here are the key news stories impacting Nephros this week:

• Neutral Sentiment: Northland Securities reiterated a “Market Perform” rating on Nephros and set a $4.00 price target, which is only modestly above the recent trading range and suggests limited near-term upside. Nephros analyst estimates and rating update
• Neutral Sentiment: The firm’s updated earnings estimates point to gradual improvement, with Northland forecasting roughly $0.03 EPS for FY2026 and $0.19 EPS for FY2027, plus quarterly EPS in the low cents range through 2027. That outlook is constructive, but not strong enough to trigger a clear bullish re-rating on its own. Nephros earnings estimates update
• Neutral Sentiment: Nephros also announced it will participate in Maxim Group’s “Health, Wellness & Longevity” Virtual Conference on July 22. Conference participation can increase visibility, but it does not by itself change fundamentals. Nephros conference announcement

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.